Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: J Immunol. 2017 Jan 6;198(4):1575–1584. doi: 10.4049/jimmunol.1601255

Figure 4.

Figure 4

Synergistic antitumor effect of anti-CD40/CpG and 14.18-IL2 IC/anti-CTLA-4. B78 melanoma cells (2×106) were injected s.c. into C57BL/6 mice on day 0. Anti-CD40 (500 mcg) was injected i.p. on day 23; CpG (25 mcg) was injected i.t. on days 26,28,30. 14.18-IL2 IC (25 mcg) was given i.t. on days 26–30; anti-CTLA-4 (200 mg) was injected i.p. on day 26,28,30,33,35,40. The results are shown as means ± SEM of tumor volumes (A) and survival (B) of 5 mice per group. C. C57BL/6 mice bearing B78 tumors received combined treatment with anti-CD40/CpG and IC/anti-CTLA-4 (clone 9D9, IgG2a) as described in Figure 4A up to day 33. On day 34 tumors were removed, and single cell suspensions were evaluated for indicated immune cells by flow cytometry. The results are shown as means ± SEM of 5 mice per group. D. C57BL/6 mice were injected s.c. with 5×105 B16 or B16-GD2 cells. Anti-CD40 was injected i.p. on day 7; CpG was injected i.t. on days 10,12,14. 14.18-IL2 IC was given i.t. on days 10–14; anti-CTLA-4 (clone 9D9, IgG2a) was injected i.p. on day 10,12,14,17,19,21. Control mice received no treatment. The results are shown as survival of 5 mice per group.